QR Code

Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study

AimsTo evaluate the efficacy and safety of dapagliflozin plus pioglitazone versus comparators on metabolic control and hepatic steatosis in adults with type 2 diabetes mellitus (T2DM), with or without metabolic dysfunction-associated steatotic liver disease (MASLD).MethodsWe conducted a systematic r...

Full description

Saved in:
Main Authors: Shashank Joshi, Shambo Samrat Samajdar, Arvind Gupta, Mithun Bhartia, Sailesh Lodha, Supratik Bhattacharyya, Krishna Seshadri, Lakshmi Nagendra, A. G. Unnikrishnan, Dakshata Padhye, Lakshmi Nalini Kopalle, Ashok Kumar Das, Om Lakhani, Jothydev Kesavadev, Ameya Joshi, Sambit Das, Smriti Gadia, Thamburaj Anthuvan
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2026-07-01
Series:Frontiers in Clinical Diabetes and Healthcare
Subjects:
combination therapy
dapagliflozin
MASLD
NAFLD
pioglitazone
SRMA
Online Access:https://www.frontiersin.org/articles/10.3389/fcdhc.2026.1733995/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items